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The kidney is formed during development by 
reciprocal interactions between the ureteric bud (UB) 
and the metanephric mesenchyme (MM), which promote 
the induction of nephron patterning and differentiation. 
Traditionally, UB and MM cells including nephron 
progenitor cells (NPCs) have been very difficult to 
isolate and maintain in culture due to their propensity 
to differentiate when outside their developmental niche. 
Remarkably, in recent years researchers have succeeded in 
prolonging the lifespan of mouse [1], rat [1], and human 
[2] NPCs in vitro, offering an avenue to expand the 
current knowledge of mammalian kidney development, 
and eventually for disease modelling and drug screening 
studies. Alternatively, renal progenitors have also been 
generated from human pluripotent stem cells (hPSCs) 
by mimicking early kidney developmental signals in 
vitro. Recently, different laboratories have been able to 
partially reproduce kidney organogenesis in a dish using 
hPSCs, successfully generating so-called kidney organoids 
[3,4,5,6]. Kidney organoids contain self-organized 
nephron-like structures composed of early podocyte 
cell clusters connected to tubular structures expressing 
markers of proximal tubules, loops of Henle and distal 
tubules [3,4,5,6]. In addition, kidney organoids display 
proximal tubular functionality in vitro, showing selective 
endocytosis of dextran cargoes [5,6], as well as responding 
to nephrotoxic agents [4,5,6].
Recent advances in the generation of kidney 
organoids in vitro together with state-of-art genome 
editing tools, including clustered regularly interspaced 
short palindromic repeats (CRISPR)/CRISPR-associated 
systems 9 (Cas9), represent a unique opportunity to study 
human kidney development and disease. Congenital 
kidney disorders can be modelled by introducing disease 
mutations in hPSCs and subsequently studying the 
disease phenotype in differentiated kidney organoids. 
Following this approach, Freedman and colleagues have 
recently reported an in vitro human model for polycystic 
kidney disease (PKD) by producing hPSCs with targeted 
biallelic mutations in the PKD1 and PKD2 genes encoding 
polycystin-1 (PC1) and polycystin-2 (PC2), respectively. 
CRISPR-mutant PKD and PKD2 knockout kidney 
organoids formed cysts in kidney tubules, recapitulating 
some characteristic features of this life-threatening renal 
disease in vitro [6]. In the same work, the authors also 
tested the function of hPSC lines that were gene edited 
so that they lacked the podocalyxin (PODXL) gene. 
PODXL-defective kidney organoids revealed junctional 
organization defects in podocyte-like cells, showing 
for the first time that hPSC-derived podocyte (hPSC-
podocytes) cells could have the potential to recapitulate 
phenotypes of glomerulopathies in vitro [6]. In a follow 
up study it was shown that hPSC-podocytes inside kidney 
organoids exhibited a differentiation stage similar to 
mammalian podocytes at the capillary loop stage (CLS), 
and were able to establish junction-rich basal membranes 
and microvillus rich apical membranes [7]. In contrast, 
PODXL knockout hPSC-podocytes had defects in the 
assembly of microvilli, which resulted in failed junctional 
migration. Importantly, these defects were also found in 
CLS glomeruli of PODXL deficient mice, suggesting that 
PODXL has an essential role in mammalian podocyte 
maturation [7]. Although hPSC-podocytes could 
complete the process of junctional migration, they were 
unable to form bona fide foot processes characteristic of 
mature podocytes. In this regard, the current inability to 
produce vascularized kidney organoids able to sustain 
the development of glomerular capillary loops could be a 
major drawback for further podocyte maturation as well as 
kidney tissue growth.
Further improvements in kidney organoid 
methodologies are required to overcome major limitations, 
such as the lack of vascularization and the generation of 
a proper collecting duct system. Increasing experimental 
evidence have shown that the biophysical properties of 
the cell milieu significantly contributes to the modulation 
of stem cell differentiation, and ultimately to tissue 
formation and function. In this regard, Freedman and 
colleagues have recently shown that adherent forces play 
a critical role in increasing or decreasing cyst formation 
[8]. By culturing mutant kidney organoids in suspension 
instead of under adherent culture conditions, the authors 
were able to establish a highly efficient model of PKD 
cystogenesis, which phenotypically resembled PKD 
patient cysts [8]. They further showed that PKD2-/- 
organoids were defective in PC1 protein expression, 
while in PKD1-/- organoids PC2 expression levels were 
unchanged from isogenic controls. Indeed, knocking down 
PC2 protein in control hPSCs induced a decrease in PC1 
protein. Altogether these findings indicated that PC2 was 
required for PC1 expression in human cells. Moreover, 
the authors proved that kidney organoid epithelia were 
able to remodel their extracellular matrix (ECM), and that 
this property was partially dependent on PC1, revealing a 
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role of the ECM microenvironment in maintaining tubular 
shape and adhesion through interactions of PC1’s long 
extracellular domain [8]. These findings highlighted the 
importance of the ECM microenvironment in maintaining 
tubular architecture, playing an essential role at the earliest 
stages of PKD.
Overall, the above discussed experiments as well 
as others, demonstrate the power of CRISPR/Cas9 
when combined with hPSCs derived organoids in order 
to explore the role of candidate genes related to kidney 
disease. Further knowledge in this area may open new 
venues for the systematic analysis of CRISPR/Cas9 
edited patient mutations in kidney organoids, offering 
ideal platforms for drug and genetic screens aimed at 
identifying novel therapeutic targets.
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